LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products

Journal of Pharmaceutical and Biomedical Analysis

Volumn 38, Issue 4, 2005, Pages 686-694

  Den Brok, Monique W J ^a   Nuijen, Bastiaan ^a   Hillebrand, Michel J X ^a   Lutz, Christian ^b   Opitz, Hans Georg ^b   Beijnen, Jos H ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b Wilex Biotechnology GmbH   (Germany)

Author keywords

Imexon; Mass spectrometry; Reversed phase liquid chromatography; Ring destroying aziridine reactions; Validation

Indexed keywords

ANTINEOPLASTIC AGENT; IMEXON;

ACCURACY; ARTICLE; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; HEXANONES; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; ONLINE SYSTEMS; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SOLUTIONS; SPECTROPHOTOMETRY, INFRARED; SPECTROPHOTOMETRY, ULTRAVIOLET; X-RAY DIFFRACTION;

EID: 20644466654     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2005.02.012     Document Type: Article

References (16)

1. U.F. Bicker R.S. Fenichal M.A. Chirigos Immune Modulation: Agents and their Mechanisms 1975 Marcel Dekker New York 447 473
2. E.M. Hersh, C.R. Gschwind, C.W. Taylor, R.T. Dorr, R. Taetle, and S.E. Salmon J. Natl. Cancer Inst. 84 1992 1238 1244
3. R.T. Dorr, J.D. Liddil, M.K. Klein, and E.M. Hersh Invest New Drugs 13 1995 113 116
4. K. Dvorakova, C.N. Waltmire, C.M. Payne, M.E. Tome, M.M. Briehl, and R.T. Dorr Blood 97 2001 3544 3551
5. B.S. Iyengar, R.T. Dorr, and W.A. Remers J. Med. Chem. 47 2004 218 223
6. ICH Steering Committee, ICH Q3A(R) Impurities in New Drug Substances, European Agency for the Evaluation of Medicinal Products, International Commission on Harmonisation, London (CPMP/ICH/2737/99), 2002. Available at: http://www.ich.org/.
7. ICH Steering Committee, ICH Q3B(R) Impurities in New Drug Products, European Agency for the Evaluation of Medicinal Products, International Commission on Harmonisation, London (CPMP/ICH/2738/99), 2003. Available at: http://www.ich.org/.
8. ICH Steering Committee, in: European Agency for the Evaluation of Medicinal Products, International Commission on Harmonisation, London (CPMP/ICH/381/95), 1994.
9. ICH Steering Committee, ICH Q2B Validation of Analytical Procedures: methodology, European Agency for the Evaluation of Medicinal Products, International Commission on Harmonisation, London (CPMP/ICH/281/95), 1996. Available at: http://www.ich.org/.
10. H. Rosing, W.Y. Man, A. Doyle, A. Bult, and J.H. Beijnen J. Liq. Chromatogr. Rel. Technol. 23 2000 329 354
11. R.W. Mitchell, J.C. Burr, and J.A. Merritt Spectrochim. Acta 23A 1967 195 207
12. W. Wang Int. J. Pharm. 203 2000 1 60
13. J. Lemoine, B. Fournet, D. Despeyroux, K.R. Jennings, R. Rosenberg, and E. De Hoffmann J. Am. Soc. Mass Spectrom. 4 1993 197 203
14. O.C. Dermer, and G.M. Ham Ethylenimine and Other Aziridines 1969 Academic Press New York pp. 106-314
15. H. Bestian Justus Liebigs Ann Chem. 566 1950 210 244
16. M.J. van Maanen, A.C. Brandt, J.M. Damen, and J.H. Beijnen Int. J. Pharm. 179 1999 55 64